Every S-3 that Autolus Therapeutics plc (AUTL) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A S-3 covers the shelf registration that lets an established company sell over time, so if you follow AUTL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AUTL filings page.
Autolus Therapeutics plc (AUTL) has filed a resale shelf registration covering up to 3,500,000 American Depositary Shares (ADSs), each representing one ordinary share, issuable upon exercise of a warrant held by Perceptive Credit Holdings V, LP. The warrant, issued under a July 30, 2026 Note Purchase Agreement, has an exercise price of $1.9314 per ADS and expires July 30, 2036, and may be exercised for cash or on a cashless basis. The ADSs may be sold from time to time by the selling securityholder through various methods and at market or negotiated prices; Autolus is not selling any securities in this registration and will not receive proceeds from any resale, though it would receive cash equal to the exercise price upon any cash exercise of the warrant. As context, Autolus is a commercial-stage biopharmaceutical company marketing its CD19 CAR-T therapy AUCATZYL (obe-cel) for relapsed or refractory B‑ALL in the United States, the United Kingdom and parts of Europe, and is advancing obe‑cel in additional oncology and autoimmune indications.
Autolus Therapeutics plc filed a shelf registration on Form S-3 to offer, from time to time, up to $150,000,000 of ordinary shares, American Depositary Shares, debt securities and warrants. The prospectus is a general shelf: specific terms and any proceeds per offering will be set forth in prospectus supplements.
As context, the company reported 266,143,286 ordinary shares issued as of December 31, 2025. The prospectus states net proceeds will be used for clinical development, manufacturing, commercialization and general corporate purposes.
Autolus Therapeutics plc filed a registration statement on Form S-3 to register the resale by selling securityholders of up to 54,584,250 American Depositary Shares (ADSs). The amount comprises 51,318,944 ADSs previously issued and 3,265,306 ADSs issuable upon exercise of outstanding warrants. The company states the registration is being filed to satisfy contractual registration rights and that Autolus will receive no proceeds from sales by the selling securityholders. The ADSs trade on Nasdaq under the symbol AUTL; the prospectus cites a closing price of $1.47 per ADS on April 9, 2026. The filing describes customary resale methods, potential hedging and short-selling by purchasers or broker-dealers, indemnification arrangements and estimated registration expenses.